Open AccessRevisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial
Author(s) -
Susan ZollaPazner,
Peter B. Gilbert
Publication year - 2019
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.00629-19
Subject(s) - immunization , vaccine trial , biology , hiv vaccine , human immunodeficiency virus (hiv) , clinical trial , vaccine efficacy , immunology , virology , antibody , bioinformatics
The RV144 vaccine trial is the only clinical study to have shown a modest but statistically significant decrease in HIV infection risk. RV144 and the subsequent studies identifying the level of V1V2-specific antibodies as a correlate of reduced infection risk are still controversial despite many papers supporting and expanding the initial study.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom